Why ChondroFiller is not currently on the NHS

ChondroFiller is not available on the NHS, and as of mid-2026 no GP referral, exceptional funding request, or Individual Funding Request (IFR) will open a route to it — the pathway simply does not yet exist. The reason is structural rather than clinical. Before NHS trusts in England can stock or commission a novel Class III medical device, the device must complete a formal health technology assessment (HTA), typically through a NICE technology appraisal or a national commissioning framework. That process has not yet been initiated for ChondroFiller. There is currently no active NICE appraisal, no pilot scheme, and no commissioning decision in progress. This is a matter of regulatory and commissioning status, not a safety or efficacy ruling against the device — it reflects where ChondroFiller sits in the HTA pipeline, not how regulators have judged its clinical merits. The position may change as evidence accumulates and a formal appraisal is eventually sought, but for now private, self-funded treatment is the only available route in the UK.

What the NHS does fund for focal cartilage repair

For patients who need NHS funding, two cell-based cartilage repair procedures are currently available through the public pathway. Autologous Chondrocyte Implantation (ACI/MACI) received NICE approval in 2017, and Spherox has been accessible via NHS England commissioning since 2018. Both are offered at specialist NHS centres — including dedicated cartilage units at the Royal National Orthopaedic Hospital in Stanmore and University Hospital Southampton — and access requires a referral to one of those centres alongside meeting published clinical eligibility criteria.

It is important to understand what these procedures involve. ACI/MACI is a two-stage process: cartilage cells are harvested arthroscopically, cultured in a laboratory, and then re-implanted in a second operating theatre procedure under general anaesthesia. Spherox follows a comparable surgical model. Rehabilitation after either procedure is typically measured in months, not weeks.

Neither option is equivalent to ChondroFiller. They differ in mechanism — cell-based surgical implantation versus an acellular injectable scaffold — in setting (operating theatre versus outpatient appointment), and in patient profile. The eligibility criteria for ACI/MACI and Spherox reflect these differences, and not every patient with a focal cartilage defect will qualify.

Patients who do not meet the criteria for either procedure, or who are seeking to avoid a surgical pathway, are effectively outside the scope of current NHS provision for this treatment category — and are most likely weighing private options.

How ChondroFiller is delivered as a private treatment

Accessing ChondroFiller privately does not require a GP referral or a specialist letter. Patients can self-refer and most clinics begin the process with a suitability assessment — either an online questionnaire or a short remote call — before any paid commitment is made.

The implant itself is a CE-marked Class III medical device: an injectable collagen scaffold manufactured by Meidrix Biomedicals GmbH in Germany and imported on a per-patient prescription basis. Because Class III device ordering carries specific regulatory obligations, only clinics with that infrastructure in place can offer it — a point worth checking when comparing providers.

The pathway typically runs in three stages. First, the treating clinician reviews an MRI scan to map the cartilage defect precisely — confirming its size, location, and the surrounding joint environment. Second, at the in-clinic treatment appointment, the collagen scaffold is placed under real-time ultrasound guidance as an outpatient procedure; intravenous antibiotic cover is given at the same visit. Third, a follow-up consultation at around six weeks allows the clinician to assess the early tissue response.

The mechanism behind the scaffold is acellular matrix-induced chondrogenesis. Rather than delivering donor cells or replacing cartilage directly, the collagen matrix provides a three-dimensional structure into which the patient's own progenitor cells — recruited from the synovium and subchondral bone — can migrate and proliferate to support endogenous repair. Published clinical series report IKDC scores improving by approximately 30 points over 12 months in appropriately selected patients; those figures represent benchmarks from published evidence, not guaranteed outcomes for any individual.

Suitability depends on defect characteristics confirmed at MRI assessment — typically a focal lesion in a well-aligned joint with intact surrounding structures.

Private health insurance — what to check before you commit

Private medical insurance is unlikely to cover ChondroFiller as a routine benefit. Major UK insurers — including Bupa and AXA — do not list the treatment as a standard funded procedure, and patients should plan for self-funding as the default scenario.

That said, the picture is not entirely closed. In clinical practice, a number of insurers — including Bupa, Aviva, and WPA — have approved cover for individual cases where the treating clinician submits the procedure under the appropriate billing categories for cartilage regeneration with a collagen scaffold. These are not blanket approvals; each case is assessed on its own merits, and outcomes vary considerably. The billing category approach is not a reliable workaround, and no patient should treat a past approval as a precedent that applies to their own policy.

The single most important step before any consultation or treatment commitment is to obtain written pre-authorisation from your insurer. Verbal confirmation — even from a named adviser — does not constitute a funding guarantee and carries no weight if a claim is later disputed. Pre-authorisation in writing, before any costs are incurred, is non-negotiable.

When exploring this route, it is worth asking the treating clinic directly which procedure categories they use for billing and whether they have experience guiding patients through insurer submission. Clinics with an established ChondroFiller pathway will typically have handled pre-authorisation requests before and can advise on what documentation insurers are likely to require.

Finding a trained ChondroFiller specialist in the UK

Provision of ChondroFiller is currently concentrated in London, and patients based in Scotland, Wales, Northern Ireland, or regional England should account for this when planning their search. A remote clinical assessment — a video consultation or an online suitability review — can usefully precede any travel commitment, allowing a clinician to review existing imaging and confirm whether an in-person appointment is warranted.

Because the treatment requires several specific capabilities, not every clinic offering injection therapies will be in a position to deliver it. Three questions are worth putting to any prospective provider: does the clinic have real-time ultrasound guidance for placement; is there MRI defect-mapping expertise to confirm lesion characteristics before any decision is made; and can the clinic place a specialist Class III medical device order? That third requirement, in particular, tends to exclude general sports-medicine injection services and GP-based procedure lists — Class III device procurement carries regulatory obligations that most generalist settings are not equipped to meet.

No definitive public registry of all UK-certified ChondroFiller providers currently exists. The market is early-stage, and provider lists may not be complete or fully current — an honest limitation that patients should factor into their search rather than assume any single directory is exhaustive. The MSK Doctors Search platform (search.mskdoctors.com) indexes UK specialists by region and treatment offered, making it a practical starting point for patients who want to identify trained practitioners in their area before deciding whether to travel to a major centre.

Key questions to ask at a ChondroFiller consultation

Before committing to a paid consultation, it helps to arrive with a handful of questions in mind — not to test the clinician, but to understand whether the clinic's experience and setup genuinely fit your situation.

Begin by asking about imaging. Any credible assessment starts with a current MRI: defect size, location, and the condition of the surrounding tissue all affect whether ChondroFiller is the right choice. A clinic prepared to discuss suitability before reviewing recent imaging is worth questioning on that point.

Ask, too, whether the team has managed a comparable case — the same joint, a similar defect profile. Experience with your specific presentation directly shapes the quality of the clinical advice you will receive.

On delivery, ask directly how the implant is placed. The answer should describe ultrasound-guided placement in an outpatient appointment — no theatre admission, no general anaesthetic. Any substantially different description warrants a follow-up question.

If ChondroFiller does not fit your presentation, a good clinician will say so and explain the alternative with reasoning. An offer to move to another injectable without that explanation is not the same as a considered recommendation.

Finally, confirm what the quoted cost covers: MRI review, the implant itself (ordered per-patient from Germany for each individual case), the injection appointment, antibiotic cover, and follow-up. A practitioner who can answer all of this without hesitation — including the per-patient import step — has run the full pathway before. That fluency across both the clinical and the logistical detail is itself a meaningful thing to carry away from the conversation.